{
    "root": "2ea9224f-5848-5255-e063-6294a90a4485",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Divalproex Sodium",
    "value": "20250221",
    "ingredients": [
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        }
    ],
    "indications": "Divalproex sodium extended-release tablets are indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features (1.1) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2) Prophylaxis of migraine headaches (1.3)",
    "contraindications": "Divalproex sodium extended-release tablet is an extended-release product intended for once-a-day oral administration. Divalproex sodium extended-release tablets should be swallowed whole and should not be crushed or chewed.",
    "warningsAndPrecautions": "Divalproex Sodium Extended-Release Tablets USP, 250 mg are available as white to off-white, capsule-shaped, biconvex, film-coated tablets imprinted with \"ZA47\" on one side and the other side plain and are supplied as follows:\n  \nUnit dose packages of 100 (10 x 10) NDC 68084-310-01\n \n                  Divalproex Sodium Extended-Release Tablets USP, 500 mg are available as white to off-white, capsule-shaped, biconvex, film-coated tablets imprinted with \"ZA48\" on one side and the other side plain and are supplied as follows:\n  \nUnit dose packages of 80 (10 x 8) NDC 68084‐415‐02\n  \nUnit dose packages of 100 (10 x 10) NDC 68084-415-01\n \n                  \n                     Storage\n                     \nStore at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].\n \n                  \n                     FOR YOUR PROTECTION: Do not use if blister is torn or broken.\n \n                  Maalox\n  ® is the registered trademark of Novartis Consumer Health.\n  \nTrisogel\n  ® is the registered trademark of Eli Lilly Corporation.\n  \nTitralac\n  ® is the registered trademark of 3M Pharmaceuticals.",
    "adverseReactions": "Divalproex sodium extended-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction \n   [see \n    Warnings and Precautions (5.1)]. \n   \n                     \n                     Divalproex sodium extended-release tablets are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder \n   [see \n    Warnings and Precautions (5.1)]. \n   \n                     \n                     Divalproex sodium extended-release tablets are contraindicated in patients with known hypersensitivity to the drug \n   [see \n    Warnings and Precautions (5.12)]. \n   \n                     \n                     Divalproex sodium extended-release tablets are contraindicated in patients with known urea cycle disorders \n   [see \n    Warnings and Precautions (5.6)]. \n   \n                     \n                     For use in prophylaxis of migraine headaches: Divalproex sodium extended-release tablets are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception \n   [see \n    Warnings and Precautions (5.2, \n    5.3, \n    5.4), and \n    Use in Specific Populations (8.1)]."
}